Kolexia
Senellart Helene Oncologie médicale
Senellart Helene
Oncologie médicale
Institut de cancérologie de l'Ouest
Saint-Herblain, France
128 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs colorectales Métastase tumorale Tumeurs du poumon Adénocarcinome Carcinomes Tumeurs neuroendocrines Carcinome pulmonaire non à petites cellules Carcinome pulmonaire à petites cellules Tumeurs de l'oesophage

Collaborateurs

Voir plus
Bennouna-Louridi Jaafar
Bennouna-Louridi Jaafar
Hôpital Foch, Suresnes, France
Hiret Sandrine
Hiret Sandrine
Institut de cancérologie de l'Ouest, Saint-Herblain, France
Touchefeu Yann
Touchefeu Yann
Hôpital Hôtel-Dieu Nantes, Nantes, France
Raoul Jean-Luc
Raoul Jean-Luc
Institut de cancérologie de l'Ouest, Saint-Herblain, France

Industries

Voir plus
Servier
6 collaboration(s)
Dernière en 2023
CanceroDigest
2 collaboration(s)
Dernière en 2022
Takeda Pharmaceutical
2 collaboration(s)
Dernière en 2020
Ipsen
1 collaboration(s)
Dernière en 2020

Dernières activités

Voir plus
TASKIN: Multicentric Randomized Phase I/II Study to Evaluate Efficacy of Trifluridine/Tipiracil Plus XB2001 (Anti-IL-1α True Human Antibody) Versus Trifluridine/Tipiracil Plus Placebo in Metastatic Colorectal Cancer Patients After Failure of Oxaliplatin, Irinotecan, Fluoropyrimidine
Essai Clinique (Centre Georges-François Leclerc)   12 février 2024
BETTER2: Randomized Phase 2 Trial Of Two Chemotherapy Regimens Plus Or Minus Bevacizumab In Patients With Well Differentiated Pancreatic Neuroendocrine Tumors
Essai Clinique (Gustave-Roussy)   07 février 2024
LOGICAN: Randomised Phase II Study Evaluating Trifluridine/Tipiracil Plus Oxaliplatin ± Nivolumab Versus FOLFOX ± Nivolumab in Patients With Gastric, Oesophagus or Gastroesophageal Junction Adenocarcinoma Locally Advanced, Recurrent or Metastatic, Ineligible for Triplet Chemotherapy
Essai Clinique (Servier)   12 octobre 2023
1555P Cell-free DNA analysis in patients with metastatic gastroesophageal adenocarcinoma: Preliminary results of the REGIRI - PRODIGE 58 ancillary study
Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023.   01 octobre 2023
Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION): A Phase II Single-arm Trial to Investigate Tepotinib in Advanced (Locally Advanced or Metastatic) Non-small Cell Lung Cancer With METex14 Skipping Alterations or MET Amplification (VISION)
Essai Clinique (Emd Serono)   15 mai 2023
Prognostic score for synchronous metastatic rectal cancer: A real-world study.
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver   01 avril 2023
Study of Pembrolizumab (MK-3475) Versus Investigator's Choice Standard Therapy for Participants With Advanced Esophageal/ Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181): A Phase III Randomized Open-Label Study of Single Agent Pembrolizumab vs Physicians' Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects With Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus That Have Progressed After First-Line Standard Therapy (KEYNOTE-181)
Essai Clinique (Merck & Co.)   09 février 2023
Prospective Multicentric Assessment of Ga-DOTANOC PET/CT in Grade 1-2 GEP-NET.
Cancers   14 janvier 2023
Prolonged response on olaparib maintenance in metastatic pancreatic acinar cell carcinoma associated with a germline BRCA 2 mutation, revealed by severe panniculitis.
Clinical case reports   12 décembre 2022
Outcome of patients with solid tumors considered for ICU admission: a single-center experience
Proceedings of Reanimation 2022, the French Intensive Care Society International Congress   22 juin 2022